Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference

Rhea-AI Summary

Exicure, Inc. (NASDAQ: XCUR) announced that CEO Matthias Schroff will present at the 2022 Chardan Genetic Medicines Conference on October 3-4, 2022. The presentation will be available on-demand starting October 3 at 4:00 PM EST for 120 days. Exicure will also conduct one-on-one investor meetings with registered attendees. The company focuses on developing nucleic acid therapies targeting RNA for neurological and hair loss disorders, supported by a skilled team and a dedicated research facility in Chicago.

Positive

• CEO Matthias Schroff's live presentation at a prominent conference may enhance investor interest.
• Exicure is developing innovative nucleic acid therapies for significant health issues, targeting RNA.
• The availability of on-demand content provides broader access to potential investors.

Negative

• None.

CHICAGO--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference, occurring October 3-4, 2022.

The presentation will be available for on-demand viewing using the virtual conference link beginning October 3, 2022 at 4:00 PM EST and will be archived for 120 days: https://wsw.com/webcast/chard14/xcur/1943406

Exicure will be taking 1x1 investor meetings with registered conference attendees.

About Exicure

Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening. For further information, see www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005015/en/

Media:

Karen Sharma

MacDougall

781-235-3060

ksharma@macdougall.bio

Source: Exicure, Inc.

FAQ

What is Exicure, Inc. focused on?

Exicure, Inc. focuses on developing next-generation nucleic acid therapies targeting RNA for neurological and hair loss disorders.

When will Exicure's CEO present at the Chardan Genetic Medicines Conference?

CEO Matthias Schroff will present at the conference on October 3-4, 2022.

How can I view Exicure's presentation from the conference?

The presentation will be available for on-demand viewing starting October 3, 2022, at 4:00 PM EST and will remain accessible for 120 days.

Is Exicure conducting any investor meetings?

Yes, Exicure will conduct one-on-one investor meetings with registered attendees at the conference.